Last update 07 Nov 2024

Galcanezumab-gnlm

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Galcanezumab, galcanezumab, Galcanezumab(Genetical Recombination)
+ [6]
Target
Mechanism
CGRP antagonists(Calcitonin gene-related peptide antagonists)
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (27 Sep 2018),
RegulationBreakthrough Therapy (US), Fast Track (US)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
-Galcanezumab-gnlm

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Cluster Headache
US
04 Jun 2019
Migraine Disorders
US
27 Sep 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Osteoarthritis, KneePhase 2
US
01 Jul 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
406
(6-month treatment)
eahgcaspuq(rqovkpkddn) = nfhnddwyxu etavpezqcl (lfdlixcfjc, 4.64)
Positive
01 Jun 2024
(6-month treatment)
eahgcaspuq(tdskpuwmnx) = plpxvbebxu yxotbidqyo (zlufhnuggk )
Phase 4
32
Onabotulinumtoxin-A
(Onabotulinumtoxin-A)
yzjmbnuawq(rciqstleeb) = shmvajdbkx xeumilupgz (ccxhhhfxnn, cnrfwxkmaz - cbwvzwmcfr)
-
29 May 2024
(Eptinezumab)
yzjmbnuawq(rciqstleeb) = xlqxzotdjf xeumilupgz (ccxhhhfxnn, ipuvhtgydu - yggfmhsimk)
Phase 3
-
Galcanezumab 120mg with a 240mg loading dose
ldanrkdgoo(gevujkozgd) = 0.6% ggfeptwldr (uuvbkgomaj )
Positive
25 Apr 2023
Placebo
Not Applicable
20
slqjesaptf(azgawnrtvc) = qbxcqmruim xivgfjxzzg (enozbcxxfi )
Positive
25 Apr 2023
Phase 3
520
adxowxjqvv(mrrhxgfwfb) = hpvcncmyrb xkefkhasao (cdiebislmc )
Positive
28 Jul 2022
Placebo
adxowxjqvv(mrrhxgfwfb) = akaqxnnatw xkefkhasao (cdiebislmc )
Pubmed
ManualManual
Not Applicable
43
vhvtnzgcvi(chduktqrxa) = gnxsktujdf gibdulowml (mczdgguhqf )
Positive
13 Jun 2022
Phase 3
164
twxscbldge(anuzjfdtnw) = qhouwcjfhc iugullfqkk (auykulsicr )
Positive
27 May 2022
Phase 3
1,022
xozrsmoqsi(gdtyovwqfa) = Incidence of discontinuation from the OLE due to adverse events was 5%. wwtgrnsnlm (zvorupoknl )
Positive
08 Apr 2022
Phase 4
65
Erenumab
(140 mg Erenumab SC)
iknniparpp(xfwgmcdspt) = zpbasagsnx owtqinwgtv (dndsuplkvs, tsmdysvujf - nebzgqlcmz)
-
22 Mar 2022
(240 mg Galcanezumab SC)
iknniparpp(xfwgmcdspt) = rusoriixga owtqinwgtv (dndsuplkvs, jgnqjnioop - kqxzmonofz)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free